Dr. Waqqas Tai is a cancer doctor who often shares health advice online. He recently revealed what the five most "lethal" ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, a ...

A neoantigen-targeting personalized cancer vaccine may be effective as adjuvant therapy in patients with high-risk clear cell renal cell carcinoma, phase 1 data suggest.

The 55-year-old, who was diagnosed with breast cancer in 2015, opened up about it all on Monday's episode of the ITV show.

TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia. See ...

The new vaccine is "personalized," meaning it is designed to train the patient's immune system to recognize and eliminate any remaining cells of that person's cancer.

The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung ...

Learn more about whether Legend Biotech Corporation or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Amicus Therapeutics, Inc. or Merus N.V. is a better investment based on AAII's A+ Investor grades, ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

The state’s life sciences industry honored its own last Thursday night at BioNJ’s annual Dinner Meeting & Innovation ...

By sharing the stories of EDI champions in science, we hope to shed light on both the importance of diversity and the ...